What is the 7th Annual Allogeneic Cell Therapies Summit?
The 7th Annual Allogeneic Cell Therapies Summit is the premier forum uniting cell therapies to advance accessible off-the-shelf approaches. Spanning from preclinical development to manufacturing to commercialization, this year's content will provide you with valuable insights at all stages of development.
This is your opportunity to hear the latest updates across a diverse set of cell developers, whether it is Gamma Delta T cells with IN8Bio, CAR-Ts with Adicet Bio, or NK cells with Senti Biosciences!
As the leading meeting for allogeneic cell therapies, you will network with large pharma including Takeda, AstraZeneca and Bristol Myers Squibb, whilst also joining top biotech companies like Adicet Bio and Caribou Bio, alongside new emerging companies such as Shinobi Therapeutics and Tr1x.
Who Will Attend this Summit?
What Topics Will Be Covered?
Solid Tumour Breakthroughs: Hear from NKILT Therapeutics, and Synaptimmune on how allogeneic therapies are targeting the tumour microenvironment to unlock entirely new indications.Â
Manufacturing at Scale: As the pressure builds to make these therapies commercially viable, learn how Tevogen and Cell BioEngines are navigating the complexities of scalable, high-quality manufacturing.Â
New Regulatory Horizons: With evolving frameworks and novel allogeneic approaches entering the clinic, Bristol Myers Squibb and Takeda reveal how they are preparing to accelerate approval timelines in 2025.Â
Beyond Oncology: In 2025, broaden your scope by discovering how Biosyngen is leveraging allogeneic platforms to address autoimmune disorders.Â
Responding to industry demand, this year's agenda features four in-depth workshops on critical topics such as mechanisms of allo-rejection, strategic donor sourcing and selection, controlled cell expansion, and tackling solid tumor challenges.Â
We have streamlined our content into two brand-new tracks to reflect your current needs.
For the first time, hear from Shinobi Therapeutics, Mendus, Tr1x Bio, Cell BioEngines, and Biosyngen - all making their speaking debuts at this must-attend global event.Â
What is New for 2025?
Why Attend in 2025?
Building on the milestones met last year, 2025 has kick started with the momentum to transform the future of allogeneic therapies.
Recent headlines include:
- Mesoblast’s approval of stem-cell based therapy for GvHD.
- Roche’s acquisition of Poseida Therapeutics.
- Sana Biotech releases promising data for Type 1 Diabetes, highlight the growing potential of universal cell therapies and CAR-Ts.
Who Will Be Speaking?
How Can I Register?
To secure your place for the summit, please visit our registration page to book online. Alternatively get in contact at [email protected] to discuss registration options further.
To ensure your company gets the most out of this meeting, we offer team discounts:Â
2 Delegates - 10% DiscountÂ
3 Delegates - 15% DiscountÂ
4+ Delegates - 20% DiscountÂ
Are there Group Discounts Available?